Clinical Trial Update: Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial updates investigate TNF-alpha antagonism effects in patients with metabolic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Metabolic Syndrome X | Phase 2, Phase 3 | Status: COMPLETED